对《STRIVE和TERRAIN试验中转移性去势抵抗性前列腺癌患者临床进展的需治疗人数分析》的勘误
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
作者信息
Schultz Neil M, Shore Neal D, Chowdhury Simon, Klotz Laurence H, Concepcion Raoul S, Penson David F, Karsh Lawrence I, Yang Hongbo, Brown Bruce A, Barlev Arie, Flanders Scott C
机构信息
Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
Carolina Urologic Research Center, Myrtle Beach, SC, USA.
出版信息
BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.
Abstract
It has been highlighted that in the original article [1] there was a typesetting mistake in the Results - NNT in Strive section. This Correction article states the incorrect and correct sentence.
摘要
需要强调的是，在原文[1]的“结果 - Strive研究中的NNT”部分存在排版错误。本勘误文章给出了错误和正确的句子。
相似文献
1
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.对《STRIVE和TERRAIN试验中转移性去势抵抗性前列腺癌患者临床进展的需治疗人数分析》的勘误
BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.
2
Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.在未经化疗的转移性去势抵抗性前列腺癌患者中，恩杂鲁胺与醋酸阿比特龙加泼尼松治疗的需治疗人数及相关增量成本。
J Med Econ. 2017 Feb;20(2):121-128. doi: 10.1080/13696998.2016.1229670. Epub 2016 Sep 16.
3
Correction to: Formative research for the design of a scalable water, sanitation, and hygiene mobile health program: CHoBI7 mobile health program.对以下内容的更正：用于可扩展的水、环境卫生和个人卫生移动健康项目设计的形成性研究：CHoBI7移动健康项目。
BMC Public Health. 2019 Aug 19;19(1):1134. doi: 10.1186/s12889-019-7477-7.
4
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.厄他培隆联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌（ELM-PC 4）患者：一项双盲、多中心、3 期、随机、安慰剂对照试验。
Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.
5
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.醋酸阿比特龙治疗化疗后进展的转移性去势抵抗性前列腺癌患者：多中心、开放标签、早期准入方案试验的最终分析。
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
6
Correction to: Pulmonary nocardiosis masquerading renascence of tuberculosis in an immunocompetent host: a case report from Nepal.对《免疫功能正常宿主中伪装成结核病复发的肺诺卡菌病：尼泊尔的一例报告》的勘误
BMC Res Notes. 2018 Jul 25;11(1):505. doi: 10.1186/s13104-018-3619-8.
7
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand.
Curr Radiopharm. 2017 Nov 10;10(3):171-177. doi: 10.2174/1874471010666170816125907.
8
Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.化疗前醋酸阿比特龙。去势抵抗性前列腺癌治疗方案建议。
Actas Urol Esp. 2014 Jun;38(5):327-33. doi: 10.1016/j.acuro.2013.10.008. Epub 2013 Dec 15.
9
Correction to: Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.对《机器学习分类器预测 Gleason 4 级前列腺癌的准确率高于经验丰富的放射科医生》一文的更正
Eur Radiol. 2020 Feb;30(2):1295. doi: 10.1007/s00330-019-06429-9.
10
Correction to: circular RNA expression profiles during the differentiation of mouse neural stem cells.对《小鼠神经干细胞分化过程中的环状RNA表达谱》的修正
BMC Syst Biol. 2019 Jan 24;13(1):14. doi: 10.1186/s12918-019-0682-2.
本文引用的文献
1
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.STRIVE 和 TERRAIN 试验中转移性去势抵抗性前列腺癌患者临床进展的需要治疗人数分析。
BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7.
Zotero 插件